CRBN Stock Analysis: Corbion | AS
Specialty Chemicals | AS, Netherlands | Market Cap: 1.310m EUR | 12M Return: 36.4% | NL0010583399 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.71M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corbion N.V. is a Dutch specialty chemicals company founded in 1903 and headquartered in Amsterdam. It produces lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-based nutritional ingredients, serving markets across Europe, the Americas, Asia, the Middle East, and Africa. The company operates through two business segments: Functional Ingredients & Solutions, and Health & Nutrition. Its extensive product portfolio spans additives and ingredients for food, feed, personal care, pharmaceuticals, and industrial applications, with a long list of branded offerings such as PURAC, PURASOLV, PURASORB, and AlgaPrime DHA. The company was previously known as CSM N.V. before rebranding to Corbion N.V. in October 2013.
As a specialty chemicals producer, Corbion operates in a sector that supplies value-added chemical inputs to a wide range of downstream industries, including food and beverage manufacturing, animal nutrition, personal care, and pharmaceuticals. Its focus on lactic acid and algae-derived ingredients places it at the intersection of the bio-based and sustainable ingredients trend, where companies develop renewable, fermentation-based alternatives to traditional petrochemical-derived products.
- Algae-based omega-3 demand grows as aquaculture feed market expands
- PLA bioplastics revenue scales on sustainable packaging regulation
- Health & Nutrition margins pressured by lactic acid feedstock costs
| Net Income: 62.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.79 > 1.0 |
| NWC/Revenue: 23.06% < 20% (prev 7.01%; Δ 16.05% < -1%) |
| CFO/TA 0.10 > 3% & CFO 144.2m > Net Income 62.2m |
| Net Debt (533.3m) to EBITDA (169.7m): 3.14 < 3 |
| Current Ratio: 1.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.4m) vs 12m ago -0.50% < -2% |
| Gross Margin: 25.05% > 18% (prev 26.10%; Δ -1.05% > 0.5%) |
| Asset Turnover: 85.16% > 50% (prev 89.21%; Δ -4.05% > 0%) |
| Interest Coverage Ratio: 5.39 > 6 (EBIT TTM 100.2m / Interest Expense TTM 18.6m) |
| A: 0.19 (Total Current Assets 635.1m - Total Current Liabilities 346.2m) / Total Assets 1.49b |
| B: 0.46 (Retained Earnings 681.8m / Total Assets 1.49b) |
| C: 0.07 (EBIT TTM 100.2m / Avg Total Assets 1.47b) |
| D: 1.03 (Book Value of Equity 755.7m / Total Liabilities 733.3m) |
| Altman-Z'' = 4.31 = AA |
| DSRI: 1.36 (Receivables 274.6m/208.4m, Revenue 1.25b/1.30b) |
| GMI: 1.04 (GM 26.10% / 25.05%) |
| AQI: 0.52 (AQ_t 0.08 / AQ_t-1 0.16) |
| SGI: 0.97 (Revenue 1.25b / 1.30b) |
| TATA: -0.06 (NI 62.2m - CFO 144.2m) / TA 1.49b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 08, 2026, the stock is trading at EUR 22.12 with a total of 58,172 shares traded. Over the past week, the price has changed by -2.64%, over one month by +1.84%, over three months by +7.69% and over the past year by +36.37%.
Current recommended Stop Loss: 21.30 (which is 3.7% or 1.6 ATR below the current price).
Corbion has no consensus analysts rating.
P/E Trailing = 21.434
P/E Forward = 12.7877
P/S = 1.0455
P/B = 1.7074
P/EG = 1.2623
Revenue TTM = 1.25b EUR
EBIT TTM = 100.2m EUR
EBITDA TTM = 169.7m EUR
Long Term Debt = 320.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 156.3m EUR (from shortTermDebt, last quarter)
Debt = 569.3m EUR (from shortLongTermDebtTotal, last quarter) + Leases 51.7m
Net Debt = 533.3m EUR (calculated: Debt 569.3m - CCE 36.0m)
Enterprise Value = 1.84b EUR (1.31b + Debt 569.3m - CCE 36.0m)
Interest Coverage Ratio = 5.39 (Ebit TTM 100.2m / Interest Expense TTM 18.6m)
EV/FCF = 24.38x (Enterprise Value 1.84b / FCF TTM 75.6m)
FCF Yield = 4.10% (FCF TTM 75.6m / Enterprise Value 1.84b)
FCF Margin = 6.03% (FCF TTM 75.6m / Revenue TTM 1.25b)
Net Margin = 4.96% (Net Income TTM 62.2m / Revenue TTM 1.25b)
Gross Margin = 25.05% ((Revenue TTM 1.25b - Cost of Revenue TTM 939.0m) / Revenue TTM)
Gross Margin QoQ = 24.47% (prev 25.65%)
Tobins Q-Ratio = 1.24 (Enterprise Value 1.84b / Total Assets 1.49b)
Interest Expense / Debt = 3.27% (Interest Expense 18.6m / Debt 569.3m)
Taxrate = 22.54% (18.1m / 80.3m)
NOPAT = 77.6m (EBIT 100.2m * (1 - 22.54%))
Current Ratio = 1.83 (Total Current Assets 635.1m / Total Current Liabilities 346.2m)
Debt / Equity = 0.75 (Debt 569.3m / totalStockholderEquity, last quarter 755.7m)
Debt / EBITDA = 3.14 (Net Debt 533.3m / EBITDA 169.7m)
Debt / FCF = 7.05 (Net Debt 533.3m / FCF TTM 75.6m)
Total Stockholder Equity = 749.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.23% (Net Income 62.2m / Total Assets 1.49b)
RoE = 8.30% (Net Income TTM 62.2m / Total Stockholder Equity 749.2m)
RoCE = 9.37% (EBIT 100.2m / Capital Employed (Equity 749.2m + L.T.Debt 320.2m))
RoIC = 6.14% (NOPAT 77.6m / Invested Capital 1.26b)
WACC = 5.95% (E(1.31b)/V(1.88b) * Re(7.43%) + D(569.3m)/V(1.88b) * Rd(3.27%) * (1-Tc(0.23)))
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.47 | Cagr: -1.62%
[DCF] Terminal Value 73.10% ; FCFF base≈85.3m ; Y1≈74.8m ; Y5≈60.4m
[DCF] Fair Price = 7.57 (EV 969.9m - Net Debt 533.3m = Equity 436.6m / Shares 57.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -90.15 | Revenue CAGR: -4.88% | SUE: 0.90 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=1.32 | Chg30d=-1.81% | Revisions=-38% | GrowthEPS=+0.2% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=1.53 | Chg30d=-1.33% | Revisions=-12% | GrowthEPS=+16.2% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: -31% (up=3, down=7)